Trial Information - Phase III

A Phase III, multicenter, open-label, randomized trial comparing the efficacy and safety of Tafasitamab plus Lenalidomide in addition to R-CHOP versus R-CHOP in high-risk patients with previously untreated Diffuse Large B-Cell Lymphoma

Protocol ID: MOR208C310

Sponsor: Morphosys

Status: OPEN TO ENROLLMENT

Contact us regarding Clinical Trials at MOHRSCH@usoncology.com
or call us at 877-664-7724